Research programme: myocardial signal transducers - Millennium

Drug Profile

Research programme: myocardial signal transducers - Millennium

Alternative Names: Myocardial signal transducers research programme - Millennium

Latest Information Update: 28 Jun 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Heart failure; Myocardial ischaemia

Most Recent Events

  • 21 Jun 2006 No development reported - Preclinical for Myocardial ischaemia in USA (unspecified route)
  • 20 Jun 2006 No development reported - Preclinical for Congestive heart failure in USA (unspecified route)
  • 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top